LLY

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason.

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Foundayo in new-to-brand prescriptions, driven by superior weight loss efficacy and fewer drug interaction restrictions. Despite setbacks, NVO is advancing late-stage candidates like CagriSema, UBT251, and zenagamtide, aiming to rival Eli Lilly's next-generation assets by the early 2030s.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.

Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disease Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science INDIANAPOLIS, July 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.

Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging.

Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.